Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MGC026 |
Synonyms | |
Therapy Description |
MGC026 is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody linked to a topoisomerase I inhibitor, which has potential antitumor activity against B7-H3 (CD276)-expressing tumor cells (Cancer Res (2024) 84 (6_Supplement): 1904). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGC026 | MGC-026|MGC 026 | CD276 Antibody 16 | MGC026 is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody linked to a topoisomerase I inhibitor, which has potential antitumor activity against B7-H3 (CD276)-expressing tumor cells (Cancer Res (2024) 84 (6_Supplement): 1904). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |